COPD

Latest Content


This cost analysis using data from the Study to Understand Mortality and Morbidity in COPD (SUMMIT) trial found that fluticasone furoate/vilanterol reduced the rates and costs of combined chronic obstructive pulmonary disease (COPD) exacerbations and revascularization/cardiovascular events versus placebo.

Researchers proposed new diagnostic criteria for chronic obstructive pulmonary disease (COPD) that seek to identify more patients in early stages of the disease, promote better care for patients, and stimulate research to slow and prevent COPD, in a paper published today in the journal Chronic Obstructive Pulmonary Diseases.